Comments to FDA: OTC Drug Products

Share page:
Docket Number:
00N-1256

This submission represents CHPA's detailed written comments as follow-up to the June meeting and is intended to complement the Association's oral presentation.

Related Posts

CHPA Statement on Valisure Citizen Petition